Removing Nitrate and Arsenic in Drinking Water Act

ARC Act of 2025 Amputation Reduction and Compassion Act of 2025

Natural Gas Tax Repeal ActThis bill eliminates a program administered by the Environmental Protection Agency that provides support for reducing methane emissions from the oil and gas sector. It also repeals a charge on methane emissions from facilities that contain petroleum and natural gas systems and emit 25,000 metric tons or more of greenhouse gases per year.

Daylight ActThis bill allows states to observe daylight saving time year-round. (States may already choose to observe standard time year-round.)

This joint resolution nullifies the final rule titled Energy Conservation Program: Energy Conservation Standards for Commercial Water Heating Equipment, which was submitted by the Department of Energy on October 6, 2023. The rule adopts more stringent energy conservation standards for commercial water heating equipment under the Energy Policy and Conservation Act in order to achieve more energy savings.

Defund Planned Parenthood Act of 2025

Barriers and Regulatory Obstacles Avoids Deployment of Broadband Access and Needs Deregulatory Leadership Act or the BROADBAND Leadership ActThis bill limits the authority of a state or locality to regulate the placement, construction, or modification of telecommunications service facilities.States and localities may not discriminate in such regulations among providers of telecommunications services, including based on the technology used to provide services. In addition, states and localities may not regulate in a manner that effectively prohibits the provision or improvement of interstate or intrastate telecommunications services.However, states and localities may charge reasonable, cost-based fees (1) to review requests to place, construct, or modify telecommunications service facilities; or (2) for the use of property owned or managed by the state or locality for the placement, construction, or modification of those facilities.States or localities must respond to requests to place, construct, or modify facilities and for other related actions by specified deadlines. Such deadlines may only be tolled by a mutual agreement between the applicant and the state or locality, or in the event that the application is incomplete and requires a supplemental submission. If a decision is not made by the deadline, the request is deemed to be approved. Further, denials of requests must be made in writing, supported by evidence, and promptly released to the public.A person adversely affected by an alleged violation of these provisions may petition the courts for expedited review of the actions of the state or locality. 

Health Care Prices Revealed and Information to Consumers Explained Transparency Act or the Health Care PRICE Transparency Act This bill provides statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. Specifically, hospitals must publish in their list of standard charges certain rates negotiated with insurers, discounts for cash payments, and billing codes. Further, hospitals generally must publish the standard charges for the services provided by the hospital that may be scheduled in advance. Additionally, insurance plans must publish the in-network and out-of-network charges for covered items and services and the negotiated prices for covered prescription drugs. Plans must provide a tool for consumers to search for this cost information. Consumers also may request additional information about the costs of specific items or services under their plans.

The HCT/P Modernization Act of 2025This bill requires the Food and Drug Administration (FDA) to provide information to stakeholders and report on the regulation of human cell and tissue products, also referred to as human cells, tissues, or cellular or tissue-based products (HCT/Ps), which are articles containing or consisting of human cells or tissues that are intended for use in a human recipient.The bill requires the FDA to conduct workshops to educate stakeholders and facilitate discussion with them on advancing the science and regulation of human cell and tissue products. The FDA must establish a public docket to receive written comments on this topic, and submit to Congress a report with recommendations on regulating these products. Additionally, the bill requires the FDA to publish on its website educational materials about the Tissue Reference Group and best practices for obtaining a recommendation about products from them. Also, annually for three years, the FDA must publish on its website information on the inquiries submitted and average response times for the Tissue Reference Group, as well as the number of human cell and tissue manufacturers that have registered with the FDA and the number of inspections the FDA has conducted with respect to these manufacturers since 2019. (The Tissue Reference Group is a working group within the FDA that receives product-specific questions from, and provides recommendations for, stakeholders on the regulation of human cell and tissue products under the FDA’s rules.) 

This bill provides statutory authority for the application of certain technical and procedural standards to systems that transmit artificial or prerecorded telephone messages generated using artificial intelligence.Specifically, the standards require (1) that such messages clearly identify and state the telephone number or address of the individual or entity initiating the call, and (2) that any system making such phone calls release a recipient’s telephone line within five seconds of notification that the recipient has ended the call. Such standards are prescribed and implemented by the Federal Communications Commission (FCC) and apply under current law to any system used to transmit an artificial or prerecorded voice message by telephone. The bill also permits the FCC to apply the standards to other technologies used to transmit artificial and prerecorded telephone messages as it deems appropriate. 

Title X Abortion Provider Prohibition ActThis bill prohibits the Department of Health and Human Services (HHS) from awarding family planning grants to entities that perform abortions or provide funding to other entities that perform abortions. To receive a grant, an entity must certify it will refrain from those activities during the grant period.The bill provides exceptions for abortions (1) in cases of rape or incest; or (2) when the life of the woman is in danger due to a physical disorder, injury, or illness. It also exempts hospitals unless they provide funds to non-hospital entities that provide abortions.HHS must submit a report to Congress annually on this prohibition.

This joint resolution nullifies the rule titled National Primary Drinking Water Regulations for Lead and Copper: Improvements (LCRI), which was submitted by the Environmental Protection Agency on October 30, 2024. The rule modifies the regulations under the Safe Drinking Water Act to further reduce lead in drinking water, including by directing water systems to replace all lead and certain galvanized service lines under their control within 10 years.

Broadband Resiliency and Flexible Investment Act

Save America’s Valuable Energy Act or the SAVE ActThis bill directs the Department of Energy to prohibit the sale of petroleum products (e.g., crude oil) from the Strategic Petroleum Reserve to entities headquartered in Russia, Belarus, Burma, China, Cuba, Iran, North Korea, Syria, or Venezuela.

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl ActThis bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.Under the bill, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term).Additionally, the bill establishes a new, alternative registration process for certain schedule I research.The bill also makes several other changes to registration requirements for conducting research with controlled substances, includingpermitting a single registration for related research sites in certain circumstances,waiving the requirement for a new inspection in certain situations, andallowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.Finally, the bill expresses the sense that Congress agrees with the interpretation of Controlled Substances Act in United States v. McCray, a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.